Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Contemporary Trends in Future of Drug Design Multi-Objective Methods for Developing a Drug

Sujitra Wongkasemjit

Numerous innovations have taken place recently in the quickly developing field of structure-based drug design. The surge of genomic, proteomic, and structural data has opened numerous new targets and opportunities for the discovery of therapeutic leads. An overview of the structure-based drug design process is given in this article, with an emphasis on the selection of a target, evaluation of the targets. A large region of selective inhibitor identification of an interest target is called structure-based drug design. Numerous computational techniques have been developed since the three-dimensional structures of pharmacological targets, primarily proteins, became available to address the difficulties involved in the drug design process. The main parameters to determine the efficacy of new chemical inhibitors are drug-likeness, drug ability of the target protein, specificity, off-target binding, etc.